Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : llama-derived VHH-Fc Antibody
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
ExeVir and Mithra Announce Manufacturing Collaboration for Innovative Covid-19 Treatments
Details : XVR011 is a single domain-based anti-SARS-CoV-2 antibody (llama-derived VHH-Fc) optimized for stability, safety, broad neutralizing capability and excellent manufacturability.
Brand Name : XVR011
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 15, 2021
Lead Product(s) : llama-derived VHH-Fc Antibody
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?